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Aminoimidazolecarboxamide ribonucleotide formyl transferase (AICARFT): Inosine 
monophosphate cyclohydrolase (IMPCH, collectively called ATIC) is a bifunctional enzyme that 
catalyses the penultimate and final steps in the purine de novo biosynthesis pathway. The 
bifunctional protein is dimeric and each monomer contains two different active sites both of 
which are capable of binding nucleotide substrates, this means to a potential total of four distinct 
binding events might be observed. Within this work we used a combination of site-directed and 
truncation mutants of ATIC to independently investigate the binding at these two sites using 
calorimetry. A single S10W mutation is sufficient to block the IMPCH active site allowing 
investigation of the effects of mutation on ligand binding in the AICARFT active site.  The 
majority of nucleotide ligands bind selectively at one of the two active sites with the exception of 
xanthosine monophosphate, XMP, which, in addition to binding in both AICARFT and IMPCH 
active sites, shows evidence for cooperative binding with communication between 
symmetrically-related active sites in the two IMPCH domains. The AICARFT site is capable of 
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independently binding both nucleotide and folate substrates with high affinity however no 
evidence for positive cooperativity in binding could be detected using the model ligands 
employed in this study. 
AICARFT,  AICAR transformylase;  AMP,  adenosine monophosphate;  
ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyl transferase:Inosine 
monophosphate cyclohydrolase; ATIC WT, ATIC Wild Type; IMPCH, inosine monophosphate 
cyclohydrolase; ITC, isothermal titration calorimetry; XMP, xanthosine monophosphate.
The bifunctional enzyme ATIC (5-aminoimidazole-4-carboxamide ribonucleotide 
WUDQVIRUP\ODVH,QRVLQHމ-monophosphate cyclohydrolase) catalyses the final two steps of the de 
novo purine biosynthetic pathway.1 This and the corresponding pyrimidine de novo synthesis 
pathway form one of two methods via which the formation of DNA and RNA nucleotide pools in 
living cells occurs.2 Although the second method, salvage synthesis, has a lower metabolic cost, 
rapidly-dividing foetal and cancer cells depend mainly on the de novo synthetic pathways and in 
many tumours there is an absolute dependence for de novo purine biosynthesis.3 Its function in 
the de novo pathway established ATIC as a target for many anti-inflammatory and antineoplastic 
agents including: methotrexate, sulfasalazine and pemetrexed.4,5 Inhibition of ATIC activity by 
these anti-folate drugs causes the accumulation of the substrate AICAR (5-aminoimidazole-4-
carboxamide ribonucleotide) in cells, activating the cellular energy sensor AMPK (adenosine 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
monophosphate-activated protein kinase), which briefly speaking suppresses inflammation.6 
More recently, cyclic peptide inhibitors of ATIC dimerization and small molecules derived from 
them have been shown to have a similar effect on AMPK.7,8 Finally, ATIC and AICAR have 
recently been implicated in the regulation of the insulin receptor autophosphorylation and its 
endocytosis.9 
The 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (AICARFT) and inosine 5'-
monophosphate cyclohydrolase (IMPCH) enzymatic activities of ATIC are catalysed by a single 
purH-encoded bifunctional polypeptide in all organisms apart from the archaea such as 
Methanococcus jannaschii.10 Structural studies of ATIC enzymes have been conducted on the 
human,11,12 chicken,13,14  bacterial15 and yeast16 proteins. The overall architectures of the avian 
and human ATIC are highly homologous as would be expected from their high sequence identity 
(82%).17 These structural analyses of the metazoan enzymes have been complemented by a broad 
range of kinetic, substrate analogue and mutagenesis studies.13,18, 19 Truncation mutant studies of 
human ATIC have shown that the AICARFT and IMPCH activities are encoded on independent 
domains.11 The AICARFT domain (residues 200±593) is responsible for the transfer of a formyl 
group from the cofactor N10-formyl tetrahydrofolate and its polyglutamylated forms to the 
substrate AICAR producing a stable formylAICAR (FAICAR) intermediate. The smaller N-
terminal domain (residues 1±199) has IMPCH activity and catalyzes the cyclization of FAICAR 
to inosine 5'-monophosphate (IMP)20 (Figure 1a). Structural studies have revealed that ATIC 
forms an intertwined dimer (Figure 1b), in which the two catalytic sites are separated by 
approximately 50 Å. 14,21 Sedimentation equilibrium and dilution experiments show that human 
PurH apoprotein exists in a monomer:dimer equilibrium mixture with a Kdim of 0.55 µM22 and 
although the transformylase activity requires dimerization, the monomeric form is sufficient for 
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the cyclohydrolase activity.23 Small molecule inhibitors of this dimerization have been reported8 
and its inhibition in mammalian cells has been tested on obese mouse models.24 It has been 
shown that inhibition of AICAR transformylase leads to decreasing of elevated blood glucose 
levels, as well as glucose tolerance improving, and body mass reduction.24 
As ATIC is a bifunctional enzyme, previous studies have addressed whether there is a kinetic 
advantage to this structural organization such as substrate channeling as observed for other 
multifunctional enzymes.25 However rapid chemical quench, stopped-flow and steady-state 
kinetics26,27,19 all indicate that channelling of FAICAR does not occur with ATIC. In fact, the 
equilibrium of the AICARFT reaction lies towards AICAR rather than the product.28,19 
Nevertheless, the higher rate of the IMPCH reaction (36 times faster)28 and the proximity of the 
AICARFT and IMPCH active sites on ATIC protein appear to be sufficient for capture of 
FAICAR by IMPCH without channeling or domain-domain communication. Kinetic studies of 
the purified metazoan enzymes using AICAR together with either 10-formyltetrahydrofolate or 
the kinetically-preferred 10-formyldihydrofolate28 yield estimates of the apparent Michaelis 
constants11,27 for these substrates in the micromolar range. Using these substrates, Szabados and 
Christopherson28 investigated the order of ligand binding and proposed that the enzyme proceeds 
via an ordered mechanism with the tetrahydrofolate substrate binding before AICAR. In this 
paper, we reinvestigate ligand binding by the enzyme using isothermal titration calorimetry. Via 
this technique, we hoped to determine whether polyglutamylation of the cofactor would allow us 
to demonstrate that the ordered binding observed using kinetics measurements could also be 
observed using equilibrium binding measurements. The two substrate-binding pockets in this 
enzyme are a confounding variable in these experiments since the AICAR substrate is likely to 
be able to bind at both the IMPCH and AICARFT active sites and we therefore sought to use 
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site-directed mutagenesis and truncated protein constructs to deconvolve the signals for ligand 
binding at each site. 
2.1 Materials 
Analytical grade reagents were obtained from Sigma Aldrich, Fisher Scientific, Alfa Aesar and 
VWR International. Water was purified using an ELGA PURLAB® Classic. DNA samples were 
purified using the Qiagen QIAquick gel extraction kit and Miniprep kit. Molecular biology 
reagents (including enzymes, plasmids and buffers) were obtained from Promega, Novagen, New 
England Biolabs, Roche Diagnostics and Invitrogen. Oligonucleotide primers were synthesised 
by Sigma-Aldrich or IDT. Laboratory plasticware and consumables were supplied by Starlab, 
Fisher Scientific and Greiner. Kanamycin 1000 x stock at 50 mg/ml was made from kanamycin 
sulfate (BioChemica). DNA ladder marker Hyperladder I was obtained from New England 
Biolabs (12 bands, 100 bp-1.5 kbp), the Molecular Weight Marker used in SDS-PAGE gel 
electrophoresis was obtained from NEB (2-212 kDa) and recombinant DNase 1 from Roche 
Diagnostics. The resin used in the Ni-NTA column was Qiagen agarose. Vectors pET28a-hATIC 
and pET28a-aATIC encoding the full-length human and avian isoforms of ATIC were acquired 
from the Benkovic and Tavassoli laboratories respectively.
2.2 Construction of Truncation and Site-Directed Mutants 
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2.3 Protein Expression and Purification 
All transformations were carried out under sterile conditions at 4 °C. Plasmids (carrying ATIC or 
one of its mutants) were transformed to chemically competent E. coli BL21(DE3) cells. Starter 
FXOWXUHVRI/%POZLWKNDQDP\FLQȝJPOwere inoculated from a single colony from the 
plates under sterile conditions, and incubated at 37 °C with shaking overnight. The starter 
cultures were added to auto-induction media (1 L) with kanamycin (final concentration 50 
ȝJPO DQG LQFXEDWHG DW  & ZLWK VKDNLQJ RYHUQLJKW 7KH FHOOV ZHUH KDUYHVWHG E\
centrifugation (JA-10, 8000 rSPPLQ&DQGVWRUHGDWí&7KHIUR]HQFHOOSHOOHWZDV
re-suspended in lysis buffer (1x PBS, 10 mM imidazole) on ice. Recombinant DNase 1 (5,000 
units/l) was added to the lysis buffer. The cell suspensions were lysed using the Constant cell 
disruption system (20 psi, 5 ml injections). Alternatively, the cell suspensions were lysed by 
sonication (40% power, 4-6 min). The cell debris was sedimented (JA- 25.50, 17000rpm, 40 
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min) and the supernatant decanted and stored on ice before purification. Ni-NTA resin (~5 ml) 
was equilibrated with lysis buffer; the lysate loaded and non-binding fractions collected. Lysis 
buffer (40 ml) followed by this same amount of wash buffer (1xPBS, 50 mM Imidazole) were 
applied to the column and wash fractions collected. Elution buffer (1x PBS, 250 mM Imidazole) 
was applied to the column and fractions containing protein (5 ml) were collected. Elution 
fractions were analysed by SDS-PAGE.  
The fractions containing the ATIC protein obtained from the Nickel-affinity column were 
concentrated to a volume of 1-2 ml via centrifugal concentration (Vivaspin and Amicon) and 
applied to a 26/60 Superdex 200 gel filtration column using a Pharmacia AKTÄ FPLC system. 
The purified ATIC was eluted using 50 mM Tris-HCl pH 7.4, 25 mM KCl buffer (called later -
ATIC buffer) at a rate of 1.0 ml/min, larger protein fragments being eluted first. Fractions were 
identified using UV absorbance (280 nm) and SDS-PAGE (using the BioRad tetragel system). 
ATIC runs as a monomer by SDS-PAGE, which is due to the denaturing conditions of the 
analysis. The molecular weight (MW) of samples was determined by electrospray ionisation 
mass spectrometry using a BrukerDaltonics® HCT UltraTM mass spectrometer and compared to 
the MW calculated by using Uniprot server (The purification data of ATIC Wild Type (WT) and 
its mutants are provided in Supplementary section). Protein concentration was calculated by 
measurement of UV absorption at 280 nm using theoretical extinction coefficients of 54320 M-1 
cm-1 (WT), 59820 M-1 cm-1 (S10W mutant) and 7450 M-1 cm-1 (IMPCH domain). 
Û& 
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2.4 ITC studies 
A MicroCalTM ITC200 (Malvern) was used to carry out the isothermal titration calorimetry 
studies. Equal buffers were used for the protein and substrate solutions, and the system was 
PDLQWDLQHGDWÛ&7KHUHIHUHQFHFHOOZDVILOOHGZLWK$7,&EXIIHUaȝ/RUZDWHUDQGWKH
sample cell filled with a known conceQWUDWLRQ RI SURWHLQ a ȝ/ - ȝ0 7KH WLWUDWLRQV
ZHUHFDUULHGRXWRYHULQMHFWLRQVîȝ/LQMHFWLRQIROORZHGE\îȝ/LQMHFWLRQV± at a 
UDWH RI  ȝ/V ZLWK D UHFRYHU\ WLPH RI -150 s. The data was fitted using NITPIC, 
thermodynamic parameters were determined using SEDPHAT, and GUSSI was used to present 
the data.30 In the case of avian ATIC titration by ligands, the data was fitted and thermodynamic 
parameters were determined using Origin software. Successful determination of the 
thermodynamic parameters was achieved using a combination of non-linear least-squares fitting, 
along with selection of an appropriate model which describes the binding interaction under 
investigation.31 In the case of every protein the ITC measurements were carried out one or two 
days after purification. 
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To confirm that AICAR binding occurs at the AICARFT site rather than the IMPCH site we 
sought to generate the isolated IMPCH and AICARFT domains. As previously noted, AICARFT 
requires dimerization for activity but IMPCH does not. A large proportion of the dimerization 
interface is an interdigitated eight-stranded E-sheet lying between the two catalytic domains. Due 
to this need for dimerization for binding in the AICARFT binding site we initially retained this 
motif in the construct for AICARFT and two constructs encoding residues 1-200 and 201-592 
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were subcloned into pET28a to generate N-terminally His-tagged constructs. Expression trials 
revealed strong overexpression for the IMPCH construct (residues 1-200) but not for the 
AICARFT construct (residues 201-592). Overexpression and purification of the IMPCH protein 
on large scale yielded dimeric protein (based on an estimated MW of 48 kDa from size-exclusion 
chromatography) consistent with the observations of Anderson et al.22 We investigated the 
folding of this protein and the effect of ligand binding on the protein using differential scanning 
fluorimetry (see Figure S1). While binding of both IMP and AICAR stabilized the IMPCH 
domain in a dose-dependent manner ('Tm ~ 9 ºC), addition of AMP showed a much smaller 
dose-independent response ('Tm ~ 3 ºC). We then repeated the ITC analysis of ligand binding to 
this protein (see Table 2, and Figure S15), observing binding of three out of four nucleotides 
(AMP did not bind consistent with the DSF results) and we observed no interaction with the 
polyglutamylated PteGlu4 as expected. In two cases, the binding of the nucleotides was 
marginally weaker than observed for the complete protein but was still sub-stoichiometric, in the 
case of IMP tighter binding was observed. This  appears to conflict with our interpretation of 
interaction with the full-length protein since AICAR appears to bind in the IMPCH active site 
and we do not observe negative cooperativity in the XMP binding. 
Since we were unable to overexpress the AICARFT domain alone, we instead mutated the 
IMPCH active-site in the full-length protein in order to block ligand binding. A single S10W 
mutation in which the indole ring of the inserted tryptophan residue is projected into the 
nucleobase binding pocket leads to a protein with a slightly lower dissociation constant for both 
AICAR and PteGlu4 (Table 3 and Figure 3). In summary, while the isolated IMPCH domain 
appears to bind AICAR with lower affinity than the intact protein, mutation of the IMPCH site in 
the full-length protein leads to apparent tighter binding of AICAR. This suggests that AICAR 
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binds at the AICARFT active site not in the IMPCH active site and that binding of AICAR by 
the isolated IMPCH domain is not physiologically relevant. This is likely to be due to the smaller 
dimerization interface in the protein leading to greater permissiveness of binding in the IMPCH 
site resulting in loss of communication between the two sites. 
We had originally hypothesized that the S10W mutation would block AICAR binding in the 
IMPCH active site. We therefore used this mutation to investigate the effect of binding of the 
nucleotide and folate ligands in the AICARFT active site and carried out sequential pairwise 
titration of the two ligands into both WT protein and the S10W mutant protein (Figures 3a, 3b 
and S9 and S13). In both cases, addition of PteGlu4 partially inhibited binding of AICAR (Table 
3). This inhibition suggests that binding of the fully oxidised folate cofactor perturbs binding of 
AICAR, supporting the hypothesis that the observed binding of AICAR is in the AICARFT 
active site. In this case we are using a model ligand for one substrate and the subtle conformation 
change in the pteridine ring relative to the dehydropteridine ring or tetrahydropteridine ring 
observed in the substrate may be sufficient to sterically prevent simultaneous binding of the 
AICAR and PteGlu4 ligands in their preferred conformations. Alternatively, the binding of both 
ligands in the Michaelis complex may be negatively cooperative ± based on this pair of ligands it 
is not possible to unambiguously distinguish these possibilities. 
AICAR interacts with the AICARFT active-site via a large number of hydrogen-bonding and 
charge-charge interactions. To unambiguously confirm that the AICAR binding observed was in 
this site, we investigated the effect of mutation of Phe590 upon binding of the ligand ± the side 
chain of this residue forms a T-shaped SS interaction with the imidazole ring of AICAR and 
removal of this interaction would be expected to lead to a small but measurable change in 
binding affinity. We generated two S10W-F590I and S10W-F590A double mutants and 
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investigated the effect of the additional mutation on binding of AICAR, PteGlu4 and AICAR in 
the presence of 100 PM PteGlu4 (Table 3, Figures 4 and S14). For both mutants, we observed no 
significant change in the affinity for PteGlu4 but a reduced affinity for AICAR. In this case, the 
reduced affinity for AICAR meant that we were not able to observe binding of AICAR in the 
presence of PteGlu4. This is consistent with this small molecule not being capable of competing 
with the tighter binding competitor ligand and conclusively demonstrates that the observed 
AICAR binding is at the AICARFT site and not at the IMPCH active site. 
4. Discussion 
In this study we originally sought to use calorimetry to investigate ligand binding in the AICAR 
formyltransferase active site. Previous kinetic studies suggest that ordered ligand binding occurs 
during catalysis with the folate cofactor binding first.1,28  In all of these studies, the non-
physiological 10-formyltetrahydrolate or 10-formyldihydrofolate cofactor is used.29  As shown 
by our calorimetric analysis, these bind with approximately 600-fold lower affinity than the 
oxidised form of the physiological product (folyl-triglutamate, PteGlu4). In our analysis, we are 
able to see binding of both substrates (10-fTHF and AICAR) to the apo-protein. Initially it was 
not possible to determine at which site (IMPCH or AICAR Tfase) the substrate AICAR binds but 
experiments using the variant protein supported the notion that binding was occurring at the 
AICAR Tfase active site, since a mutation in the IMPCH active site had little effect (actually a 
small apparent increase in affinity) but mutation in the AICAR Tfase site reduced binding 
significantly. Binding of ligands in this site has previously been shown to be dependent upon 
protein dimerization and it is therefore possible that the S10W mutation stabilizes this 
multimerization slightly increasing the protein dimerization.  
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AICAR, AMP and XMP exhibit distinct binding preferences ± with AMP and AICAR binding 
solely in the AICAR Tfase active site and XMP binding in both active sites. The most striking 
feature of this analysis is the negative cooperativity observed for binding of XMP in the IMPCH 
active site. In their crystal structure of 1m9n, Wolan et al. modelled the electron density in both 
IMPCH active sites (for both monomers) as two conformationally-distinct XMP molecules, 
showing that the C2 carbonyl in one of these molecules is held in a planar conformation but in 
the second the C2 carbonyl is bent out of the plane by ~20°.12  This distortion led the authors to 
suggest that under physiological conditions, half-the-sites reactivity may be occurring in the 
IMPCH active sites of ATIC.12 Our calorimetric analysis provides preliminary supporting 
analysis for this hypothesis since while binding of one molecule is enthalpically favourable, 
binding of the second is not consistent with the observed distortion. The lower binding 
stoichiometry of IMP supports this hypothesis ±an amino group in this position cannot be 
sufficiently distorted to permit binding. This limitation appears to be released in the isolated 
IMPCH domain, with loss of negative cooperativity for XMP and an increased stoichiometry of 
binding for IMP suggesting that the eight-stranded E-sheet C-terminal to the IMPCH domain is 
critical to this regulatory communication. It is also possible that binding of XMP has a regulatory 
role ± tight binding of XMP in one active site may be sufficient to inhibit binding of formyl 
AICAR in the second active site or catalysis of cyclisation. Since XMP is the intermediate 
between the pathway to GMP from the product IMP this could provide a regulatory role. 
It is clear that the AICAR Tfase active site can bind either substrate first. If the reported ordered 
binding mechanism of Szabados and Christopherson27 is correct then the Enzyme-AICAR 
complex is not catalytically competent. We had hoped that patterns of enhanced or inhibited 
second substrate binding would reveal cooperativity in binding but our analysis indicates that 
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binding of AICAR and the oxidised co-factor in their favoured geometries are mutually 
exclusive preventing confirmation of cooperative binding using these substrates and calorimetry. 
Such an analysis would still be possible using the singly reduced dihydrofolyl triglutamate were 
this to be produced. The strong binding of the oxidised cofactor also highlights the importance of 
maintaining the cellular pool of reduced folate cofactors and suggests an additional, indirect 
cellular mode of action for the antifolate inhibitors of dihydrofolate reductase. 
4.1 Conclusion 
That work shows the first attempt to characterise ligand binding by human ATIC using 
calorimetry. This analysis was complicated by the presence of multiple, distinct binding sites, 
however for the majority of ligands it is possible to use a combination of site-directed 
mutagenesis and competition experiments to identify the binding site and decompose the binding 
process. Despite the many detailed structural analysis of this enzyme already reported, this study 
further proves that this complex dimeric enzyme has many more hidden intricacies to be 
revealed. 
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Figure Captions 
 
Figure 1. a) Catalytic activity of ATIC. Aminoimidazolecarboxamide ribonucleotide (AICAR) is 
transformed into formyl-aminoimidazolecarboxamide ribonucleotide (fAICAR) using either a 
10-formyltetrahydrofolate or 10-formyldihydrofolate cofactor. In vivo the cofactors are poly- -
glutamylated. fAICAR is subsequently cyclised to form inosine monophosphate (IMP). b) 
Structure of human ATIC (1pkx) showing the intertwined dimeric structure. XMP is shown 
bound in the IMPCH active site (red, left). The AICARFT  active site is adjacent to the 
potassium binding site (purple, right). Molecular graphics and analyses were performed with the 
UCSF Chimera package.1 c) Structures of ligands used for ITC calorimetric experiments in this 
study. 
 
Figure 2. ITC thermograms for ligands binding to full-length human ATIC after exhaustive 
dialysis a) AICAR b) PteGlu4 and c) XMP binding to human ATIC, d) XMP binding to human 
ATIC in the presence of 1.1 equivalents of AICAR (saturating concentration), e) full binding 
model required to explain binding of XMP to full-length ATIC at four sites, f) empirical model 
used to fit of thermogram c suggesting that one pair of symmetrically disposed binding sites are 
independent whereas two show negative cooperativity. i.e. Kd1=Kd0n/1n, Kd2=Kd1n/2n and Kd3 = 
Kdn0/n1 = Kdn1/n2, g) binding model used to fit binding of XMP in the presence of saturating 
AICAR. Derived dissociation constants are within error of the equivalent parameters in empirical 
model f. 
 
Figure 3. ITC thermograms for AICAR binding to a) full-length ATIC, b) ATIC-S10W and c) 
isolated IMPCH domain. All titrations were carried out at the 25ºC. d) Structure of the IMPCH 
active site with XMP bound (1m9n), showing relationship between lysine residues and the 
phosphate group of the substrate and the position of Ser10 relative to the purine ring of the 
substrate. We hypothesized the indole ring in a S10W mutant would fill this pocket. 
 
Figure 4. ITC thermograms for a. AICAR binding to full-length ATIC-S10W in the presence of 
100 µM PteGlu4, b. AICAR binding to full-length ATIC-S10W/F590I and c. AICAR binding to 
ATIC-S10W/F590A in the presence of 100 µM PteGlu4 showing complete loss of binding. d. 
Structure of the ICAR Tfase active site with AICAR bound (1m9n), showing relationship 
between mutated Phe590 and the imidazole base of AICAR. Loss of this T-VKDSHG ʌ-ʌ
interaction is sufficient to prevent effective competition between PteGlu4 and AICAR for binding 
to the active site. 
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Table 1.  Results of global fitting of small molecule binding to full-length human ATIC analysed 
by isothermal titration calorimetry ± no changes in affinity occur as a result . All titrations were 
carried out at 25 ºC with protein concentrations of 70-77 µM and small molecule concentrations 
in the range 1-1.5 mM. *NB The magnitude of the fitted binding parameters for XMP binding are 
strongly co-dependent and dependent upon the assumed binding model. These are included for 
indicative purposes only.  n = number of repeat experiments used for global fitting 
Table 2.  Result of small molecule binding to IMPCH mutant of ATIC protein. All titrations 
were carried out at 25 ºC (single titrations) 
Table 3. Calculated parameters for binding of AICAR and PteGlu4 to the ATIC-WT and ATIC-
S10W site-directed mutants.
 
All experiments were carried out at 25ºC. The concentration of 
proteins was in a range 58-77 µM, concentration of AICAR and PteGlu4 1 mM.  
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Ligand n Kd [µM] 
ǻ+ 
[kcal mol-1] 
 
ǻ* 
[kcal mol-1] 
ǻ6 
[cal mol-1 K-1] 
AICAR  6 19.5 ± 3.3 -9.7 ± 0.6 
-6.4 ± 0.1 -10.9 ± 2.1 
PteGlu4  5 0.23± 0.04 -12.6 ± 0.1 -9.1 ± 0.1 -11.8 ± 0.6 
PteGlu3  2 0.53± 0.15 -10.8 ± 0.3 -8.6 ± 0.2 -7.5 ± 1.2 
PteGlu2 1 7.1 ± 3.4 -9.44 ± 1.3 -7.0 ± 0.4 -8.1 ± 4.3 
10f-THF 1 132 ± 12 -5.6 ± 0.3 -5.3 ± 0.1 -0.9 ± 1.0 
AMP  2 14.3 ± 1.5 -6.6 ± 0.3 -6.6 ± 0.1 -0.1 ± 1.1 
AICAR in 
presence of AMP 
2 32 ± 21 -6.5 ± 1.3 
-6.1 ± 0.4 -1.4 ± 4.6 
XMP  
(3-site binding 
model) 
3 
Kd1 = 1.4 ± 0.3 
Kd2 = 55 ± 7 
Kd3 = 7.0 ± 1.1 
-4.9 ± 0.1 
16.7 ±  0.1 
-10.8 ± 0.7 
-8.0 ± 0.1 
-5.8 ± 0.1 
-7.0 ± 0.1 
10.3 ± 0.5 
75.5 ± 0.6 (!) 
-12.6 ± 2.5 
XMP in presence 
of AICAR 
( 2-site binding 
model) 
1 
Kd1= 6.6  ± 2.4 
Kd2= 25 ± 14 
-2.07 ±0.37 
5.44 ± 0.75 
-7.1  ± 0.2 
-6.3 ± 0.4 
16.8 ± 1.4 
39.3 ± 2.8 (!) 
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Ligand incA Kd [µM] 
ǻ+ 
[kcal mol-1] 
 
AICAR 0.27 ± 0.03 21.7 ±5.0 -6.25 ± 0.79 
IMP 0.37± 0.08 21.4 ± 11.2 -6.92 ± 1.13 
XMP 
0.14± 0.05 
(incB) 
12.7 ± 5.7 -5.02 ± 0.70 
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Protein 
 
AICAR PteGlu4 
AICAR (enzyme  pre-treated 
with 100 PM PteGlu4) 
Kd >ȝM] 
 
ǻ+ 
[kcal mol-1] 
 
Kd >ȝM] 
 
ǻ+ 
[kcal mol-1] 
 
Kd >ȝM] 
ǻ+ 
[kcal mol-1] 
 
ATIC-WT 19.5 ± 3.3 -8.5 ± 0.10 0.23 ± 0.03 
 
-12.6± 0.1 94 ± 9 -3.6± 0.3 
S10W 9.5 ± 1.0 -9.9± 0.56 0.078 ± 0.050 -11.6 ± 0.4 66 ± 18 -1.8± 0.15 
S10W-F590A 34.1± 5.0 -10.3 ± 0.25 0.20±  0.04 -10.6 ± 0.1 No binding No binding 
S10W-F590I  62 ± 23 -3.3 ± 0.2 0.47±  0.12 -13.2 ± 0.3 No binding No binding 
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